We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Tesaro (NASDAQ:TSRO) is up more than 16% year to date (as of the writing of this article). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Tesaro's business and drug pipeline.
Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.